<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03894553</url>
  </required_header>
  <id_info>
    <org_study_id>HSR180040</org_study_id>
    <nct_id>NCT03894553</nct_id>
  </id_info>
  <brief_title>Focused Ultrasound (FUS) Mesencephalotomy for Head &amp; Neck Cancer Pain</brief_title>
  <official_title>Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy for Pain Palliation in Head &amp; Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeff Elias, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed pilot study will investigate the safety and initial effectiveness of focused
      ultrasound lesioning of the contralateral mesencephalon for severe, opioid-resistant pain
      associated with head and neck cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study is designed as a prospective, open-label clinical trial of stereotactic FUS
      mesencephalotomy in 6 subjects with treatment-refractory pain from head and neck cancer.
      Primary safety assessments will be made throughout the study period of 6 months following the
      procedure. Primary efficacy outcome is determined by comparing the difference in baseline
      NPRS to 3 months post treatment. All subjects receiving treatment will be followed for the
      six month study period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months post-intervention</time_frame>
    <description>Number of participants with treatment-related adverse events, as assessed from adverse event reporting throughout the 6 month study period. Additional measures of safety will be made with MRI evaluation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numeric Pain Rating Scale</measure>
    <time_frame>3 months post-intervention (will also be assessed at 7 days, 1 month, and 6 months post-intervention)</time_frame>
    <description>Will compare the change of WORST pain experienced in 24 hours before (baseline) and at 3 months following unilateral FUS mesencephalotomy as determined from the 11-point numeric pain rating scale (0-10), with 0 being no pain and 10 being the worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>Baseline, 7 days, 1 month, 3 months, and 6 months post-intervention</time_frame>
    <description>Change from baseline scores to post-intervention time points (see below), as measured by a patient questionnaire that asks patients to describe the change (if any) compared to their condition prior to treatment in activity, limitations, symptoms, emotions, and overall quality of life, related to their painful condition. The options include no change, almost the same, a little better, somewhat better, moderately better, better, and a great deal better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS scale v1.0 - Pain Intensity 3a</measure>
    <time_frame>Baseline, 7 days, 1 month, 3 months, and 6 months post-intervention</time_frame>
    <description>Change from baseline scores to post-intervention time points (see below). The first two items in the Pain Intensity item bank assess pain intensity utilizing a 7-day recall period (items include the phrase &quot;the past 7 days&quot;) while the last item asks patient to rate their pain intensity &quot;right now.&quot; The Pain Intensity instrument is available for adults (ages 18+). Scale includes range from 1-5, with 1 = &quot;Had no pain&quot; and 5 = &quot;Very severe&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS scale v2.0 - Neuropathic Pain Quality 5a</measure>
    <time_frame>Baseline, 7 days, 1 month, 3 months, and 6 months post-intervention</time_frame>
    <description>Change from baseline scores to post-intervention time points (see below), as assessed by patient questionnaire that asks about pain quality in the past 7 days, specifically asking if the pain has felt like pins and needles, tingly, stinging, electrical, or numb, on a scale from 1-5, with 1 = &quot;Not at all&quot; and 5 = &quot;Very much&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS scale v2.0 - Nociceptive Pain Quality 5a</measure>
    <time_frame>Baseline, 7 days, 1 month, 3 months, and 6 months post-intervention</time_frame>
    <description>Change from baseline scores to post-intervention time points (see below), as assessed by patient questionnaire that asks about pain quality in the past 7 days, specifically asking if the pain has felt sore, tender, achy, deep, or steady, on a scale from 1-5, with 1 = &quot;Not at all&quot; and 5 = &quot;Very much&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS scale v1.0 - Pain Behavior 7a</measure>
    <time_frame>Baseline, 7 days, 1 month, 3 months, and 6 months post-intervention</time_frame>
    <description>Change from baseline scores to post-intervention time points (see below), as assessed by patient questionnaire that measures self-reported external manifestations of pain in the past 7 days, including actions and reactions that can be either verbal or nonverbal, and involuntary or deliberate. Measured on a scale from 1-6, with 1 = &quot;Had no pain&quot; and 6 = &quot;Always&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS scale v1.0 - Pain Interference 8a</measure>
    <time_frame>Baseline, 7 days, 1 month, 3 months, and 6 months post-intervention</time_frame>
    <description>Change from baseline scores to post-intervention time points (see below), as assessed by patient questionnaire that measures self-reported consequences of pain on relevant aspects of one's life in the past 7 days. Includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Also incorporates items probing sleep and enjoyment in life. Measured on scale from 1-5, with 1 = &quot;Not at all&quot; and 5 = &quot;Very much&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS - Ca Item Bank v1.0 - Emotional Distress-Anxiety</measure>
    <time_frame>Baseline, 7 days, 1 month, 3 months, and 6 months post-intervention</time_frame>
    <description>Change from baseline scores to post-intervention time points (see below), as assessed by patient questionnaire that measures self-reported fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness, restlessness), and somatic symptoms related to arousal (racing heart, dizziness), in the past 7 days. Measured on scale from 1-5, with 1 = &quot;Never&quot; and 5 = &quot;Always&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS - Ca Item Bank v1.0 - Emotional Distress-Depression</measure>
    <time_frame>Baseline, 7 days, 1 month, 3 months, and 6 months post-intervention</time_frame>
    <description>Change from baseline scores to post-intervention time points (see below), as assessed by patient questionnaire that measures self-reported negative mood (sadness, guilt), views of self (self-criticism, worthlessness), and social cognition (loneliness, interpersonal alienation), as well as decreased positive affect and engagement (loss of interest, meaning, and purpose), in the past 7 days. Somatic symptoms (changes in appetite, sleeping patterns) are not included, which eliminates consideration of these items' confounding effects when assessing patients with comorbid physical conditions. Measured on a scale from 1-5, with 1 = &quot;Never&quot; and 5 = &quot;Always&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS - Ca Item Bank v1.0 - Fatigue</measure>
    <time_frame>Baseline, 7 days, 1 month, 3 months, and 6 months post-intervention</time_frame>
    <description>Change from baseline scores to post-intervention time points (see below), as assessed by patient questionnaire that measures a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The Fatigue short form is universal rather than disease-specific. It assesses fatigue over the past seven days. Measured on a scale from 1-5, with 1 = &quot;Never&quot; and 5 = &quot;Always&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS - Ca Bank v1.1 - Physical Function</measure>
    <time_frame>Baseline, 7 days, 1 month, 3 months, and 6 months post-intervention</time_frame>
    <description>Change from baseline scores to post-intervention time points (see below), as assessed by patient questionnaire that measures self-reported capability rather than actual performance of physical activities. Measured on a scale from 5 to 1, with 5 = &quot;Without any difficulty&quot; and 1 = &quot;Unable to do&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Catastrophizing Scale</measure>
    <time_frame>Baseline, 7 days, 1 month, 3 months, and 6 months post-intervention</time_frame>
    <description>Change from baseline scores to post-intervention time points (see below), as assessed by patient questionnaire that asks participants to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily morphine equivalents (milligrams)</measure>
    <time_frame>Baseline, 7 days, 1 month, 3 months, and 6 months post-intervention</time_frame>
    <description>Change of the amount of morphine that is used by patient daily, in daily morphine equivalents (in milligrams), from baseline through 6 months post-intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Location of lesion in the x, y, z dimensions in mm</measure>
    <time_frame>7 days and 3 months post-intervention</time_frame>
    <description>The location of the lesion will be measured in the x, y, and z dimensions, and will be reported in mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Precision of lesion in the x, y, z dimensions and two dimensional radial vector in mm</measure>
    <time_frame>7 days and 3 months post-intervention</time_frame>
    <description>The precision of the lesion will be measured in the x, y, and z dimensions, but also in a two dimensional radial vector, all reported in mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of lesion in mm3</measure>
    <time_frame>7 days and 3 months post-intervention</time_frame>
    <description>The volume of the lesion will be measured in mm3.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Cancer of Head and Neck</condition>
  <condition>Pain, Face</condition>
  <condition>Pain, Neck</condition>
  <arm_group>
    <arm_group_label>FUS Mesencephalotomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive unilateral stereotactic focused ultrasound mesencephalotomy using the ExAblate Neuro device for severe, opioid-resistant pain associated with head and neck cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ExAblate Neuro</intervention_name>
    <description>Unilateral stereotactic focused ultrasound lesioning of the contralateral mesencephalon</description>
    <arm_group_label>FUS Mesencephalotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, between 18 and 75 years, inclusive

          2. Subjects with head and neck cancer, including one of the following:

               -  Cancer that arises in the head and neck region: nasal cavity, sinuses, lips,
                  mouth, salivary glands, throat, or larynx (typically squamous cell carcinoma)

               -  Cancer occurring in the nasopharynx, skin, thyroid gland, and eye

               -  Lymphoma

               -  Sarcoma

          3. Craniofacial or cervical pain related to the cancer that meets all of the following
             criteria:

               -  Severe defined by: Worst NPRS score of â‰¥ 5 out of 10 at current visit and the
                  subject reports having a similar level of pain for at least the past two months.

               -  Pain is medication-refractory to all three tiers of the WHO cancer pain ladder.
                  Thus, adequate trials of at least 3 prescription medications that will include a
                  'weak' and a 'strong' opioid. An adequate medication trial is defined as a
                  therapeutic dose of each medication without sufficient effect.

               -  Duration of greater than 6 months

          4. Mesencephalon contralateral to the pain can be targeted by the ExAblate Neuro device.
             The region of the mesencephalon must be apparent on MRI. Additional MRI sequences
             including inversion-recovery and DTI may be utilized to refine the target.

          5. Subjects who are able and willing to give consent and able to attend all study visits

          6. Subjects who are able to communicate sensations during the focused ultrasound
             treatment

          7. Stable prescribed doses of all symptomatic pain medications for 30 days prior to
             screening visit.

        Exclusion Criteria:

          1. Idiopathic trigeminal neuralgia

          2. Trigeminal neuropathic pain from trauma, infection, or iatrogenic

          3. Post-herpetic neuralgia

          4. Headache syndromes like migraine, cluster headache

          5. Temporomandibular joint syndrome

          6. Atypical facial pain or pain related to a somatoform disorder

          7. Subjects deemed poor candidates by a multidisciplinary team of cancer and palliative
             care clinicians:

               1. Significant clinician concern about reliability of subject-reported information,
                  such as subject in active process of seeking disability for neuropathic pain

               2. Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as
                  defined by the criteria outlined in the DSM-V as manifested by one (or more) of
                  the following occurring within a 12 month period: Recurrent substance use
                  resulting in a failure to fulfill major role obligations at work, school, or home
                  (such as repeated absences or poor work performance related to substance use;
                  substance-related absences, suspensions, or expulsions from school; or neglect of
                  children or household). Recurrent substance use in situations in which it is
                  physically hazardous (such as driving an automobile or operating a machine when
                  impaired by substance use)

               3. Recurrent substance-related legal problems (such as arrests for substance related
                  disorderly conduct)

               4. Continued substance use despite having persistent or recurrent social or
                  interpersonal problems caused or exacerbated by the effects of the substance (for
                  example, arguments with spouse about consequences of intoxication and physical
                  fights).

          8. Subjects with active psychiatric illness will be excluded. For the purpose of this
             study, active psychiatric illness includes:

               1. Exhibiting current suicide ideation and/or a history of suicide attempt within
                  past 2 years

               2. been hospitalized for the treatment of a psychiatric illness within the past 2
                  years

               3. received transcranial magnetic stimulation for depression treatment

               4. received electroconvulsive therapy for depression

               5. any presence or history of psychosis

          9. Subjects with unstable cardiac status including:

               1. Unstable angina pectoris on medication

               2. Subjects with documented myocardial infarction within six months of protocol
                  entry

               3. Significant congestive heart failure defined with ejection fraction &lt; 40

               4. Subjects with unstable ventricular arrhythmias

               5. Subjects with atrial arrhythmias that are not rate-controlled

         10. Severe hypertension (diastolic BP &gt; 100 on medication)

         11. Subjects with standard contraindications for MR imaging such as non-MRI compatible
             implanted metallic devices including cardiac pacemakers, size limitations, etc.

         12. On medications that increases the bleeding risk, based on the published guidelines
             which are currently recognized by the American Society of Regional Anesthesia and Pain
             Medicine, American Academy of Pain Medicine and the North American Neuromodulation
             Society (Reg Anesth Pain Med 2015;40: 182-212); specifically:

               1. Aspirin or another antiplatelet medication (clopidogrel, prasugrel, ticlopidine,
                  abciximab) for the last 7 days prior to treatment.

               2. Oral, subcutaneous or intravenous anticoagulant medications, such as oral vitamin
                  K inhibitors for the last 7 days, non-vitamin K inhibitor oral anticoagulant
                  (dabigatran, apixaban, rivaroxaban) for the last 72 hours.

               3. Intravenous or subcutaneous heparin-derived compounds for the last 48 hours.

         13. Individuals who are not able or willing to tolerate the required prolonged stationary
             supine position during treatment (can be up to 4 hours of total table time.)

         14. Subjects participating or have participated in another clinical trial in the last 30
             days

         15. Subjects with risk factors for intraoperative or postoperative bleeding from a
             documented coagulopathy or if their serum coagulation studies (platelet count, PT,
             PTT, and INR) exceed the institutional laboratory limits.

         16. Subjects with brain tumors or any significant intracranial mass.

         17. Any illness that in the investigator's opinion preclude participation in this study

         18. Pregnancy or lactation

         19. Legal incapacity or limited legal capacity

         20. Subjects with a deep brain stimulation implant

         21. Skull density ratio, calculated from the baseline non-contrasted head CT, is less than
             0.4

         22. History of hemorrhagic stroke or cerebrovascular event within the past year of
             treatment exhibiting incomplete resolution

         23. Subjects whose primary pain is other than craniofacial neuropathic pain.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Elias</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Patterson</last_name>
    <phone>434-243-1435</phone>
    <email>rfusbrain@hscmail.mcc.virginia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia UVA Health, University Hospital</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Patterson</last_name>
      <phone>434-243-7336</phone>
      <email>mwp5f@virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Jeff Elias, MD</investigator_full_name>
    <investigator_title>Professor of Neurological Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neck Pain</mesh_term>
    <mesh_term>Facial Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

